# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Citigroup analyst Yigal Nochomovitz downgrades Calliditas Therapeutics (NASDAQ:CALT) from Buy to Neutral and announces $39 p...
Jefferies analyst Maury Raycroft downgrades Calliditas Therapeutics (NASDAQ:CALT) from Buy to Hold and lowers the price targ...
Stifel analyst Annabel Samimy downgrades Calliditas Therapeutics (NASDAQ:CALT) from Buy to Hold and lowers the price target ...
Asahi Kasei's $1.1 billion acquisition of Calliditas Therapeutics offers 208 SEK per share in cash. The deal boosts Asahi K...